Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma

Oncolytic viro-immunotherapy holds promise for cancer treatment. While immune activation can be robustly triggered by oncolytic viruses, negative feedback is often upregulated in the tumour microenvironment (TME). Lactate accumulation, signal transducer and activator of transcription 3 (STAT3) activation, indoleamine 2,3-dioxygenase 1 (IDO1) expression, and myeloid-derived suppressor cell (MDSC)…

Read the full article here

Source: British Journal of Cancer

Categories: Hem/Oncs

Tags: hepatocellular

Tweets with this article

British Journal of Cancer

Day 12: Yu et al. present findings that provide a rationale for targeting reprogrammed metabolism together with oncolytic virus-mediated viro-immunotherapy for #hepatocellular #carcinoma treatment. https://t.co/xP9Xrf6yWS #CancerMetabolism

British Journal of Cancer – • 75th Anniversary of the British Journal of Cancer

Editorial 75th anniversary of the British Journal of…

British Journal of Cancer February 20, 2023

Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis – British Journal of Cancer

Cigarette smoking is the main risk factor for head and neck cancer (HNC) and many HNC patients are active smokers at diagnosis. We conducted a…

British Journal of Cancer August 26, 2022

Digital Imaging

BJC’s Digital Imaging series is open to receiving submissions assessing: State-of-the-art in digital imaging technology and computational output; …

British Journal of Cancer August 26, 2022

Liquid Biopsy

In recent years we have seen continued growth in the field of precision medicine. Developments in technology have yielded the ability to detect many …

British Journal of Cancer August 26, 2022

A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis – British Journal of Cancer

Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years after diagnosis. There…

British Journal of Cancer August 11, 2022

Journal News | British Journal of Cancer

Journal News

British Journal of Cancer August 3, 2022

Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation

Multiple mechanisms have been proposed that lead to reduced effectiveness of trastuzumab in HER2-positive gastric cancer (GC), yet resistance to trastuzumab remains a challenge in…

British Journal of Cancer June 19, 2022

TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-κB signaling pathway – British Journal of Cancer

Colorectal cancer (CRC) is prevalent worldwide and is often challenged by treatment failure and recurrence due to resistance to radiotherapy. Here, we aimed to identify…

British Journal of Cancer June 17, 2022

POH1/Rpn11/PSMD14: a journey from basic research in fission yeast to a prognostic marker and a druggable target in cancer cells – British Journal of Cancer

POH1/Rpn11/PSMD14 is a highly conserved protein in eukaryotes from unicellular organisms to human and has a crucial role in cellular homoeostasis. It is a subunit…

British Journal of Cancer May 10, 2022

HIF-1α stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/β-catenin signalling pathway

This study aimed to clarify the significance of the crosstalk between hypoxia-inducible factor-1α (HIF-1α) and the Wnt/β-catenin pathway in oesophageal squamous cell carcinoma (ESCC). The…

British Journal of Cancer May 9, 2022

Related Articles